Abstract:Background: Accumulating evidence has highlighted the potential role of long non-coding RNAs (lncRNAs) in the biological behaviors of hepatocellular carcinoma (HCC). Here, we elucidated the function and possible molecular mechanisms of the effect of lncRNA-AGAP2-AS1 on the biological behaviors of HCC. Methods: EdU, Transwell and flow cytometry were used to determine proliferation, migration, invasion and apoptosis of HCC cells in vitro. The subcutaneous tumor model and lung metastasis mouse model in nude mice was established to detect tumor growth and metastasis of HCC in vivo. The direct binding of miR-16-5p to 3'UTR of ANXA11 was confirmed by luciferase reporter assay. The expression of AGAP2-AS1 and miR-16-5p in HCC specimens and cell lines were detected by real-time PCR. The correlation among AGAP2-AS1 and miR-16-5p were disclosed by a dual-luciferase reporter assay, RIP assay and biotin pull-down assay. Results: Here, we demonstrated that AGAP2-AS1 expression was up-regulated in HCC tissues and cell lines, especially in metastatic and recurrent cases. Gain- and loss-of-function experiments indicated that AGAP2-AS1 promoted cell proliferation, migration, invasion, EMT progression and inhibited apoptosis of HCC cells in vitro and in vivo. Further studies demonstrated that AGAP2-AS1 could function as a competing endogenous RNA (ceRNA) by sponging miR-16-5p in HCC cells. Functionally, gain- and loss-of-function studies showed that miR-16-5p promoted HCC progression and alteration of miR-16-5p abolished the promotive effects of AGAP2-AS1 on HCC cells. Moreover, ANXA11 was identified as direct downstream targets of miR-16-5p in HCC cells, and mediated the functional effects of miR-16-5p and AGAP2-AS1 in HCC, resulting in AKT signaling activation. Clinically, AGAP2-AS1 and miR-16-5p expression were markedly correlated with adverse clinical features and poor prognosis of HCC patients. We showed that hypoxia was responsible for the overexpression of AGAP2-AS1 in HCC. And the promoting effects of hypoxia on metastasis and EMT of HCC cells were reversed by AGAP2-AS1 knockdown. Conclusions: Taken together, this research supports the first evidence that AGAP2-AS1 plays an oncogenic role in HCC via AGAP2-AS1/miR-16-5p/ANXA11/AKT axis pathway and represents a promising therapeutic strategy for HCC patients.Funding Statement: This study was supported by grants from the National Natural Science Foundation of China (81572847, 81402039).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: The protocols for these animal experiments were approved by the Ethics Review Committee of Xi’an Jiaotong University.All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of The First Affiliated Hospital of Xi’an Jiaotong University and with the 1964 Helsinki declaration and its later amendments. ALL written informed consent to participate in the study was obtained from HCC patients for samples to be collected from them

NCAPG2 Overexpression Promotes Hepatocellular Carcinoma Proliferation and Metastasis Through Activating the STAT3 and NF-κB/miR-188-3p Pathways

MNS1 Promotes Hepatocarcinogenesis and Metastasis Via Activating PI3K/AKT by Translocating Β‐catenin and Predicts Poor Prognosis

Overexpression of Non-Smc Condensin I Complex Subunit G Serves As a Promising Prognostic Marker and Therapeutic Target for Hepatocellular Carcinoma

NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling

Silencing non-SMC chromosome-associated polypeptide G inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells

microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2

E2F1-mediated Up-regulation of NCAPG Promotes Hepatocellular Carcinoma Development by Inhibiting Pyroptosis

IFITM3 Regulates NCAPG Through Phosphorylation to Influence the Invasion and Metastasis of HCC

Genome-wide CRISPR Knockout Screens Identify NCAPG As an Essential Oncogene for Hepatocellular Carcinoma Tumor Growth

NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression

NCAPG2 Promotes Tumour Proliferation by Regulating G2/M Phase and Associates with Poor Prognosis in Lung Adenocarcinoma

IFITM3 influences the invasion and metastasis of hepatocellular carcinoma by regulating NCAPG through phosphorylation

Long Non-Coding RNA AGAP2-AS1, Functioning As a Competitive Endogenous RNA, Upregulates ANXA11 Expression by Sponging Mir-16-5p and Promotes Proliferation and Metastasis in Hepatocellular Carcinoma

NFAT2 Overexpression Suppresses the Malignancy of Hepatocellular Carcinoma Through Inducing Egr2 Expression

NCAPG promotes the proliferation of hepatocellular carcinoma through the CKII-dependent regulation of PTEN

NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

MicroRNA-181c suppresses growth and metastasis of hepatocellular carcinoma by modulating NCAPG

Lnc-SNHG5 Promoted Hepatocellular Carcinoma Progression Through the RPS3-NFκB Pathway.

Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma.

Long noncoding RNA GPC3-AS1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.

CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway